Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Por:
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R and Castellano D
Publicada:
1 jun 2020
Resumen:
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Filiaciones:
Powles T:
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Kockx M:
HistogeneX N.V., Wilrijk, Belgium
Rodriguez-Vida A:
Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
Duran I:
Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
Crabb SJ:
Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
Van Der Heijden MS:
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Szabados B:
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
:
Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Gravis G:
Institut Paoli-Calmettes, Marseille, France
Herranz UA:
Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Protheroe A:
Department of Medical Oncology, Churchill Hospital, Oxford, UK
Ravaud A:
Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France
Maillet D:
Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
Mendez MJ:
Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
Suarez C:
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Linch M:
Department of Medical Oncology, University College London Hospital, London, UK
Prendergast A:
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
van Dam PJ:
HistogeneX N.V., Wilrijk, Belgium
Stanoeva D:
HistogeneX N.V., Wilrijk, Belgium
Daelemans S:
HistogeneX N.V., Wilrijk, Belgium
Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
Mariathasan S:
Genentech, San Francisco, CA, USA
Tea JS:
Genentech, San Francisco, CA, USA
Mousa K:
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
Banchereau R:
Genentech, San Francisco, CA, USA
Castellano D:
Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
|